# First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study

> **NCT00537901** · NA · COMPLETED · sponsor: **King Faisal Specialist Hospital & Research Center** · enrollment: 100 (actual)

## Conditions studied

- Colonic Neoplasms
- Rectal Neoplasms

## Interventions

- **RADIATION:** First-Line Bevacizumab and Chemotherapy
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00537901
- **Lead sponsor:** King Faisal Specialist Hospital & Research Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2015-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00537901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00537901, "First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00537901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*